Abstract 4191
Background
Breast cancer (BC) is primarily a disease of older or post menopausal women. It has been suggested that BC arising in young women is a unique biological subset characterized by less hormone sensitivity and higher HER2 (epidermal growth factor receptor) expression. This study was performed to compare the tumour biology between pre menopausal (PrM) and post menopausal (PoM) women.
Methods
New diagnosis of early BC from 2011-2015 in the South East Cancer Centre were included. The patients were divided into PrM (
Results
Data from 497 patients were obtained. 235 (47.3%) were PrM and 262 (52.7%) were PoM. Age range PrM group vs PoM group (29-54 vs 55-91). The differences between the groups was statistically significant on pathology subtype (p = 0.003), T stage (p = 0.033), and N stage (p = 0.008). Ki67 and grade were not statistically significant. The mean ki67 across biology subtypes (ER/PR/HER2/Ki67) in the PrM group was higher. PrM group had more grade III disease (33.2% vs 30.9%). Table 1: Distribution of tumour biology according to menopausal status.
| Pre Menopausal n = 235 | Post Menopausal n = 262 | P value | |
|---|---|---|---|
| Age Range | 29-54 | 55-91 | ConclusionsPre menopausal women in this Irish population had poorer tumour biology compared to their Post menopausal counterpart. Aggressive measures should be taken in the treatment of these women to reduce the incidence of local recurrence and metastases. Clinical trial identificationNone Legal entity responsible for the studyUniversity Hospital Waterford FundingUniversity Hospital Waterford DisclosureAll authors have declared no conflicts of interest. Resources from the same session2354 - The clinicopathologic features and treatment of 607 hindgut neuroendocrine tumor (NET) patients at a single institutionPresenter: Seung Tae Kim Session: Poster Display Resources: Abstract 2594 - Neuroendocrine carcinomas of the colorectal origin - Polish experiencePresenter: Agnieszka Kolasińska-Ćwikła Session: Poster Display Resources: Abstract 2539 - Neuroendocrine neoplasms of the appendix including goblet cell carcinoidsPresenter: Agnieszka Kolasinska-Cwikla Session: Poster Display Resources: Abstract 1245 - Prognostic validity of AJCC staging system in neuroendocrine tumors of the appendixPresenter: Amir Mehrvarz Sarshekeh Session: Poster Display Resources: Abstract 3902 - Enhancer of zest homolog 2 (EZH2) expression in well and moderately differentiated pancreatic neuroendocrine tumor (pNET)Presenter: Riccardo Marconcini Session: Poster Display Resources: Abstract 3882 - Differential clinical and pathological characteristics of hereditary neuroendocrine pancreatic tumours (NEPT)Presenter: Gema Marín Zafra Session: Poster Display Resources: Abstract 2296 - Natural course of thyroid cancer nodules compared with benign thyroid nodulesPresenter: Kyung-Jin Yun Session: Poster Display Resources: Abstract 4083 - Reassessment of proliferative activity at disease progression in neuroendocrine neoplasmsPresenter: Noemi Cicchese Session: Poster Display Resources: Abstract 3866 - 18F-FDG-PET to predict disease progression in advanced digestive neuroendocrine neoplasmsPresenter: Maria Rinzivillo Session: Poster Display Resources: Abstract 3651 - UK phase IV, observational study to assess quality of life in patients (pts) with pancreatic neuroendocrine tumours (pNETS) receiving treatment with everolimus: The “real-world” OBLIQUE studyPresenter: John Ramage Session: Poster Display Resources: Abstract This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|